Taipei Exchange - Delayed Quote TWD

TAHO Pharma (6467.TWO)

59.10

+2.00

+(3.50%)

At close: 2:59:43 PM GMT+8

Key Events

Loading Chart for 6467.TWO

Previous Close 57.10
Open 57.20
Bid 57.10 x --
Ask 59.10 x --
Day's Range 55.60 - 59.10
52 Week Range 32.25 - 90.50
Volume 150,682
Avg. Volume 641,408
Market Cap (intraday) 3.037B
Beta (5Y Monthly) -0.16
PE Ratio (TTM) --
EPS (TTM) -3.69
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

Taho Pharmaceuticals Ltd., a pharmaceutical company, develops products using transdermal and transmucosal systems in Taiwan. The company's portfolio includes TAH4411 Ondansetron ODF for the treatment of chemotherapy-induced nausea and vomiting; TAH3311 apixaban oral film, which is in phase 3 clinical trial for patients with Dysphagia; TAH3341 apixaban oral extend release film for patients with Dysphagia; TAH2211 Buprenorphine/Naloxone sublingual film, which is in phase 1 clinical trial for opioid addiction; TAH2231 Naloxone Buccal film , which is in phase 1 clinical trial for opioid overdose; TAH9922 atomoxetine oral liquid, which is in phase 1 clinical trial; and TAH9901 methylphenidate patch, which is in phase 1 clinical trial for the treatment of deficit and hyperactivity disorder. The company was founded in 2010 and is based in Taipei, Taiwan.

www.tahopharma.com

14

Full Time Employees

December 31

Fiscal Year Ends

Sector

Drug Manufacturers - Specialty & Generic

Industry

Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6467.TWO

33.11%

TSEC CAPITALIZATION WEIGHTED ST (^TWII)

5.66%

1-Year Return

6467.TWO

11.79%

TSEC CAPITALIZATION WEIGHTED ST (^TWII)

2.76%

3-Year Return

6467.TWO

11.79%

TSEC CAPITALIZATION WEIGHTED ST (^TWII)

37.25%

5-Year Return

6467.TWO

11.79%

TSEC CAPITALIZATION WEIGHTED ST (^TWII)

100.93%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

59.10

+3.50%

Mkt Cap TWD 3.037B

Industry Drug Manufacturers—Specialty & Generic

Orient Pharma Co., Ltd.

33.45

+1.36%

Mkt Cap TWD 7.461B

Industry Drug Manufacturers—Specialty & Generic

InnoPharmax Inc.

17.55

-2.23%

Mkt Cap TWD 1.888B

Industry Drug Manufacturers—Specialty & Generic

Anxo Pharmaceutical Co., Ltd.

16.05

-1.23%

Mkt Cap TWD 895.818M

Industry Drug Manufacturers—Specialty & Generic

Handa Pharmaceuticals, Inc.

80.20

+0.50%

Mkt Cap TWD 12.634B

Industry Drug Manufacturers—Specialty & Generic

Original BioMedicals Co., Ltd.

12.05

+0.42%

Mkt Cap TWD 795.204M

Industry Drug Manufacturers—Specialty & Generic

Winston Medical Supply Co., Ltd.

102.00

-0.97%

Mkt Cap TWD 1.879B

Industry Drug Manufacturers—Specialty & Generic

UniPharma Co., Ltd.

14.50

-0.68%

Mkt Cap TWD 514.765M

Industry Drug Manufacturers—Specialty & Generic

Allied Biotech Corporation

17.95

-0.55%

Mkt Cap TWD 1.716B

Industry Drug Manufacturers—Specialty & Generic

Golden Biotechnology Corporation

13.85

-1.42%

Mkt Cap TWD 2.247B

Industry Drug Manufacturers—Specialty & Generic

General Biologicals Corporation

15.50

+0.32%

Mkt Cap TWD 927.287M

Industry Drug Manufacturers—Specialty & Generic

Valuation Measures

    Annual 

As of 5/14/2025

Market Cap

2.89B
Enterprise Value

2.41B
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

5.60
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

--
Return on Equity (ttm)

--
Revenue (ttm)

-894k
Net Income Avi to Common (ttm)

-148.91M
Diluted EPS (ttm)

-3.69

Balance Sheet and Cash Flow

Total Cash (mrq)

219.01M
Total Debt/Equity (mrq)

7.86%
Levered Free Cash Flow (ttm)

--